A detailed history of D. E. Shaw & Co., Inc. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 647,032 shares of SAGE stock, worth $3.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
647,032
Holding current value
$3.63 Million
% of portfolio
0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.02 - $13.08 $2.27 Million - $4.22 Million
322,761 Added 99.53%
647,032 $4.67 Million
Q2 2024

Aug 14, 2024

BUY
$10.58 - $17.9 $1.74 Million - $2.95 Million
164,933 Added 103.51%
324,271 $3.52 Million
Q1 2024

May 15, 2024

SELL
$18.62 - $26.95 $1.78 Million - $2.57 Million
-95,329 Reduced 37.43%
159,338 $2.99 Million
Q4 2023

Feb 14, 2024

BUY
$17.1 - $22.26 $897,151 - $1.17 Million
52,465 Added 25.95%
254,667 $5.52 Million
Q3 2023

Nov 14, 2023

SELL
$16.75 - $48.98 $4.17 Million - $12.2 Million
-249,070 Reduced 55.19%
202,202 $4.16 Million
Q2 2023

Aug 14, 2023

BUY
$40.65 - $59.54 $123,454 - $180,822
3,037 Added 0.68%
451,272 $21.2 Million
Q1 2023

May 15, 2023

SELL
$37.27 - $46.57 $5.26 Million - $6.58 Million
-141,214 Reduced 23.96%
448,235 $18.8 Million
Q4 2022

Feb 14, 2023

SELL
$32.2 - $43.61 $3.61 Million - $4.89 Million
-112,035 Reduced 15.97%
589,449 $22.5 Million
Q3 2022

Nov 14, 2022

SELL
$32.28 - $43.27 $1.91 Million - $2.56 Million
-59,201 Reduced 7.78%
701,484 $27.5 Million
Q2 2022

Aug 15, 2022

SELL
$27.52 - $37.99 $4.56 Million - $6.3 Million
-165,851 Reduced 17.9%
760,685 $24.6 Million
Q1 2022

May 16, 2022

SELL
$30.71 - $45.71 $2.08 Million - $3.1 Million
-67,733 Reduced 6.81%
926,536 $30.7 Million
Q4 2021

Feb 14, 2022

SELL
$37.06 - $47.11 $9.71 Million - $12.3 Million
-262,022 Reduced 20.86%
994,269 $42.3 Million
Q3 2021

Nov 15, 2021

SELL
$40.26 - $57.37 $2.45 Million - $3.49 Million
-60,852 Reduced 4.62%
1,256,291 $55.7 Million
Q2 2021

Aug 16, 2021

SELL
$54.88 - $79.29 $30.4 Million - $44 Million
-554,732 Reduced 29.64%
1,317,143 $74.8 Million
Q1 2021

May 17, 2021

SELL
$70.65 - $96.76 $22.8 Million - $31.3 Million
-323,012 Reduced 14.72%
1,871,875 $140 Million
Q4 2020

Feb 16, 2021

SELL
$58.41 - $89.06 $15.7 Million - $23.9 Million
-268,179 Reduced 10.89%
2,194,887 $190 Million
Q3 2020

Nov 16, 2020

BUY
$41.13 - $62.45 $14 Million - $21.3 Million
340,910 Added 16.06%
2,463,066 $151 Million
Q2 2020

Aug 14, 2020

BUY
$25.95 - $43.15 $44.3 Million - $73.7 Million
1,708,926 Added 413.55%
2,122,156 $88.2 Million
Q1 2020

May 15, 2020

BUY
$26.15 - $77.24 $8.8 Million - $26 Million
336,537 Added 438.81%
413,230 $11.9 Million
Q4 2019

Feb 14, 2020

SELL
$60.18 - $154.77 $1.62 Million - $4.17 Million
-26,950 Reduced 26.0%
76,693 $5.54 Million
Q3 2019

Nov 14, 2019

BUY
$140.29 - $189.96 $14.3 Million - $19.4 Million
102,097 Added 6603.95%
103,643 $14.5 Million
Q3 2018

Nov 14, 2018

SELL
$138.11 - $169.04 $13.4 Million - $16.5 Million
-97,363 Reduced 98.44%
1,546 $218,000
Q2 2018

Aug 14, 2018

BUY
$140.36 - $175.76 $13 Million - $16.2 Million
92,366 Added 1411.68%
98,909 $15.5 Million
Q1 2018

May 15, 2018

SELL
$152.15 - $192.33 $4.79 Million - $6.06 Million
-31,500 Reduced 82.8%
6,543 $1.05 Million
Q4 2017

Feb 14, 2018

BUY
$60.72 - $167.34 $2.31 Million - $6.37 Million
38,043
38,043 $6.27 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $333M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.